# Hematopoietic Biorepository and Cellular Therapy Shared Resource

> **NIH NIH P30** · CASE WESTERN RESERVE UNIVERSITY · 2020 · $125,786

## Abstract

HEMATOPOIETIC BIOREPOSITORY AND CELLULAR THERAPY SHARED RESOURCE
PROJECT SUMMARY/ABSTRACT
The Hematopoietic Biorepository and Cellular Therapy Shared Resource (Hematopoietic SR) is an essential
asset to Case Comprehensive Cancer Center (Case CCC) members' research, illustrated by the breadth of
scientific program involvement and reflected in the large number of investigators who use this SR. Last year
alone, over 50 investigators, 51% of whom were Case CCC members, accounting for 68% of total usage, from
all 7 of the Center’s Programs used the SR. The mission of the Hematopoietic SR is to provide resources and
services related to the procurement, processing, production, storage, banking, analysis and distribution of cells
derived from human blood, bone marrow, and umbilical cords. The SR also operates a Clinical Cellular
Therapy facility that supports clinical-grade cell manufacturing for investigational and standard of care therapy.
The Specific Aims of the Hematopoietic SR are to:
 1. Enable access to annotated clinical blood and bone marrow samples to support basic and translational
 research. An active IRB is maintained to consent and procure blood and bone marrow samples and
 related case and tissue data from cancer patients and healthy donors for distribution to Case CCC
investigators.
 2. Assist users with specialized hematopoietic cell assays. Guidance and services are provided to enable
 investigators to perform specialized hematopoietic cell assays such as colony assays.
 3. Support the development and implementation of cellular therapy clinical trials. Support is provided in all
 aspects of clinical cell therapy, from assisting with regulatory approval to oversight and manufacture of
 clinical grade cells.
At last review, the Hematopoietic SR was rated Excellent merit. Throughout the current funding cycle (2012-
2016), the Hematopoietic SR provided services to 106 registered users, 44 (42%) of whom are Case CCC
members, representing all 7 of the Case CCC programs.
The Hematopoietic SR maintains a biorepository of annotated collected samples for use in research and
assists investigators with specialized hematopoietic assays such as CFU assays and bone marrow-derived
mesenchymal stem cell isolation. The cellular therapy component of the SR, designated as the Cellular
Therapy Service, supports clinical cellular therapy activities from the preclinical phase through clinical trial
implementation. Support capabilities include assistance in the design and preparation of cells for Good
Laboratory Practices (GLP) safety studies, navigation of the regulatory pathway, clinical protocol development,
Investigational New Drug Application (IND) preparation, sourcing of clinical grade supplies and reagents, and
scale up from research to clinical operations, including preparation of investigational clinical therapy grade
cellular products.

## Key facts

- **NIH application ID:** 9904141
- **Project number:** 5P30CA043703-30
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** David Wald
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $125,786
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9904141

## Citation

> US National Institutes of Health, RePORTER application 9904141, Hematopoietic Biorepository and Cellular Therapy Shared Resource (5P30CA043703-30). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9904141. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*